Medipattern™ Corporation to Install 100th B-CAD License at Metropolitan Diagnostic Imaging Group, LLC

TORONTO, ONTARIO--(Marketwire - May 08, 2009) - Attention: Business/Financial Editors

The Medipattern Corporation (“Medipattern”) (TSX VENTURE: MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, proudly announces the signing of another Enterprise Wide B-CAD-FOR-LIFE™ managed service contract with Metropolitan Diagnostic Imaging Group LLC (MDIG), pushing the total licenses worldwide to over 100. MDIG services the metropolitan New York area with locations in Manhattan, Forest Hills, Queens, Brooklyn and three locations in Long Island. B-CAD® Computer Aided Detection (CAD) for breast ultrasound imaging will be implemented throughout the multi-site practice. B-CAD is available through three different sales models. Customers may purchase, lease or they may gain the value of B-CAD through the managed service plan called B-CAD-FOR-LIFE; where they pay one monthly fee for the service. The total B-CAD license count includes a mix of purchased, leased and managed service units. With this order the majority of the licenses will be in the United States.

“Metropolitan Diagnostic has 13 radiologists that operate out of seven sites and is committed to providing imaging excellence in each of its operations with consistent patient care. One of the main benefits we see in B-CAD is a comprehensive reporting system that helps organize and report data in one easy step. Anything you can do to help organize information is a step in the right direction; B-CAD is definitely a step in the right direction,” commented Alan Winakor, President of Metropolitan Diagnostic Imaging Group. “We are committed to the highest standards of service so that we meet and exceed the expectations of our patients and referring physicians. To accomplish this, we strive to deliver the best outpatient care. We see B-CAD as adding to this high standard. Consistent information across multi-site practices like ours is difficult to maintain, B-CAD allows for a consistent template and reporting for all practices within the group. We conduct approximately 1000 breast ultrasound procedures per month and look forward to gaining all the benefits of the B-CAD system throughout our practice,” concluded Winakor.

“We are very pleased to be working closely with Metropolitan Diagnostic Imaging Group and the reception our B-CAD-FOR-LIFE program has received,” added Jeff Collins, CEO of The Medipattern Corporation. “B-CAD-FOR-LIFE has been gaining momentum in recent weeks and provides a scalable, economic solution for our clients so they can use B-CAD and gain all the benefits of the system without the upfront costs. The three month grace period before the first monthly fee is due is especially beneficial to clients and further adds to the B-CAD-FOR-LIFE value proposition. Medipattern is proud to welcome MDIG to the B-CAD user family and we congratulate our reseller Amy Eriksen of Physicians Consultant Medical Sales of New York for facilitating this transaction.”

2009 Upcoming Events:

- BIC (Breast Imaging Conference), September 4-5, 2009 in Nashville, TN partnered with GE

- RSNA (Radiological Society of North America), November 29 to December 3, 2009, Chicago, IL

About The Medipattern Corporation:

Medipattern® (TSX VENTURE: MKI) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company’s website at: www.medipattern.com.

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern’s performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern’s current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential”, and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company’s corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.